Prime time for prospective randomized trials of targeted therapies with validated targets in lung cancer: FDA perspective

被引：0
|
作者：
Malik, Shakun [1 ]
Justice, Robert [1 ]
Sridhara, Rajeshwari [1 ]
Waxman, Ian [1 ]
Pazdur, Richard [1 ]
机构：
[1] US FDA, CDER, Silver Spring, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S235 / S236
页数：2
相关论文
共 50 条
  • [11] Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials
    Perrone, F
    Di Maio, M
    Budillon, A
    Normanno, N
    CURRENT OPINION IN ONCOLOGY, 2005, 17 (02) : 123 - 129
  • [12] Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis
    Tan, Aaron C.
    Tan, Sze Huey
    Zhou, Siqin
    Peters, Solange
    Curigliano, Giuseppe
    Tan, Daniel S. W.
    CANCER TREATMENT REVIEWS, 2022, 104
  • [13] Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review
    Gouverneur, Amandine
    Salvo, Francesco
    Berdai, Driss
    Moore, Nicholas
    Fourrier-Reglat, Annie
    Noize, Pernelle
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (01) : 15 - 23
  • [14] Clinical Efficacy of Osimertinib in Targeted Therapies of Patients with Non Small Cell Lung Cancer A Randomized Controlled Trial
    Zhuo, De-bin
    Zheng, Gui-lin
    Lin, Qing-yu
    Lin, Juan
    Wang, Shan-zuan
    ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, 2021, 43 (06): : 879 - 887
  • [15] Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC)
    Reungwetwattana, Thanyanan
    Weroha, Saravut J.
    Molina, Julian R.
    CLINICAL LUNG CANCER, 2012, 13 (04) : 252 - 266
  • [16] Are we achieving the current waiting time targets in lung cancer treatment? Result of a prospective study
    Devbhandari, M
    Soon, S
    Quennell, R
    Krysiak, R
    Shah, R
    Jones, M
    LUNG CANCER, 2005, 49 : S200 - S200
  • [17] UK waiting time targets in lung cancer treatment: are they achievable? Results of a prospective tracking study
    Devbhandari, Mohan P.
    Soon, Sing Yang
    Quennell, Pauline
    Barber, Philip
    Krysiak, Piotr
    Shah, Rajesh
    Jones, Mark T.
    JOURNAL OF CARDIOTHORACIC SURGERY, 2007, 2 (1)
  • [18] UK waiting time targets in lung cancer treatment: are they achievable? Results of a prospective tracking study
    Mohan P Devbhandari
    Sing Yang Soon
    Pauline Quennell
    Philip Barber
    Piotr Krysiak
    Rajesh Shah
    Mark T Jones
    Journal of Cardiothoracic Surgery, 2
  • [19] Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study
    Torrecillas, S.
    Perrot, E.
    Geriniere, L.
    Locatelli-Sanchez, M.
    Laffay, L.
    Souquet, P. -J.
    Couraud, S.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2016, 72 (01) : 25 - 34
  • [20] Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective
    Mattana, Francesco
    Muraglia, Lorenzo
    Barone, Antonio
    Colandrea, Marzia
    Diffalah, Yasmina Saker
    Provera, Silvia
    Cascio, Alfio Severino
    Sale, Emanuela Omodeo
    Ceci, Francesco
    CANCERS, 2024, 16 (09)
12345